Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2016 / Cilt: 24 - Sayı: 4

Fallot tetralojili olguların miyokardiyal korunmasında esmololün etkisi

The effect of esmolol on myocardial protection in patients with tetrology of Fallot

Pages
627–632
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Using an intraoperative esmolol infusion including the cardiopulmonary bypass in children is safe and reduces the postoperative inotropic score.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: In this article, we examined the effects of intraoperative esmolol infusion on myocardial protection in children operated on for tetralogy of Fallot.Methods: The study involved 50 pediatric patients (29 boys, 21 girls; mean age 12.6±2 months; range 9 to 20 months) operated on for tetralogy of Fallot between January 2014 and November 2015.
📊
Key Findings & Data:We started the esmolol infusion with the induction of anesthesia (0.05 mg/kg/min) and, then, reduced the dose by half (0.025 mg/kg) during the cardiopulmonary bypass.
💡
Conclusion & Impact:Using an intraoperative esmolol infusion including the cardiopulmonary bypass in children is safe and reduces the postoperative inotropic score.
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Background: In this article, we examined the effects of intraoperative esmolol infusion on myocardial protection in children operated on for tetralogy of Fallot.Methods: The study involved 50 pediatric patients (29 boys, 21 girls; mean age 12.6±2 months; range 9 to 20 months) operated on for tetralogy of Fallot between January 2014 and November 2015. We randomly divided the children into two groups and started esmolol infusion as an intraoperative agent for one group (study group), and with normal saline infusion for the other (control group). We started the esmolol infusion with the induction of anesthesia (0.05 mg/kg/min) and, then, reduced the dose by half (0.025 mg/kg) during the cardiopulmonary bypass. We took blood samples for creatine kinase-MB, troponin I, and lactate 10 minutes after the tracheal intubation, five minutes before the cardiopulmonary bypass, five minutes after the cardiopulmonary bypass, at the end of the surgery, at the four hours postoperatively, and on the first postoperative day. We recorded the hemodynamic parameters.Results: The levels of creatine kinase-MB, troponin I and lactate were found to be significantly higher in the control group than the study group (p<0.05). The mean arterial pressures did not differ between the groups; however, we found that the heart rate in the study group was significantly lower than the control group (p<0.05). We found lower inotropic scores in the study group (p<0.05).Conclusion: In pediatric cardiac surgery, the use of intraoperative esmolol may be effective in protecting from myocardium damage. Using an intraoperative esmolol infusion including the cardiopulmonary bypass in children is safe and reduces the postoperative inotropic score.

Özet

Amaç: Bu çalışmada, Fallot tetralojisi nedeniyle ameliyat edilen çocuklarda ameliyat sırası esmolol infüzyonunun miyokardın korunması üzerine olan etkileri araştırıldı.Ça lış ma pla nı: Ocak 2014 - Kasım 2015 tarihleri arasında Fallot tetralojisi nedeniyle ameliyat edilen 50 çocuk hasta (29 erkek, 21 kız; ort. yaş 12.6±2 ay; dağılım 9-20 ay) çalışmaya dahil edildi. Çocuklar rastgele iki gruba ayrıldı ve gruplardan birine ameliyat sırasında esmolol infüzyonu (çalışma grubu) ve diğer gruba serum fizyolojik infüzyonu (kontrol grubu) başlandı. Esmolol infüzyonuna anestezi indüksiyonu ile başlandı (0.05 mg/kg/dk.) ve ardından kardiyopulmoner baypas sırasında doz yarıya indirildi (0.025 mg/kg). Kreatin kinaz-MB, troponin I ve laktat için kan örnekleri trakeal entübasyondan 10 dk. sonra, kardiyopulmoner baypastan beş dk. önce, kardiyopulmoner baypastan beş dk. sonra, ameliyat sonunda, ameliyat sonrasında dördüncü saatte ve ameliyat sonrası birinci günde alındı. Hemodinamik parametreler kaydedildi.Bul gu lar: Kreatin kinaz-MB, troponin I ve laktat düzeyleri kontrol grubunda, çalışma grubundan anlamlı olarak yüksek bulundu (p<0.05). Gruplar arasında ortalama arter basınçları farklılık göstermedi; ancak, kalp hızı çalışma grubunda kontrol grubundan anlamlı olarak düşük bulundu (p<0.05). Çalışma grubunda inotrop skoru daha düşük bulundu (p<0.05).So nuç: Pediyatrik kalp cerrahisinde ameliyat sırası esmolol kullanımı miyokardı hasardan korumada etkin olabilir. Kardiyopulmoner baypası da kapsayacak şekilde çocuklarda ameliyat sırası esmolol infüzyonu kullanımı güvenlidir ve ameliyat sonrası inotrop skorunu azaltmaktadır.

🔖

Cite This Article

GÜZELMERİÇ, F., CEYRAN, H., ŞAVLUK, Ö. F., HATEMİ, A., TUNÇER, E., YAVUZ, Y. (2022). Fallot tetralojili olguların miyokardiyal korunmasında esmololün etkisi. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 24 - Sayı: 4, 627–632. https://ajindex.com/articles/424122

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Mossad EB, Farid I. Vital organ preservation during surgery for congenital heart disease. In: Lake CL, Booker PD, editors. Pediatric cardiac anesthesia. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 266-90.
  2. Modi P, Imura H, Caputo M, Pawade A, Parry A, Angelini GD, et al. Cardiopulmonary bypass-induced myocardial reoxygenation injury in pediatric patients with cyanosis. J Thorac Cardiovasc Surg 2002;124:1035-6.
  3. Bronicki RA, Chang AC. Management of the postoperative pediatric cardiac surgical patient. Crit Care Med 2011;39:1974-84.
  4. Angeli F, Verdecchia P, Karthikeyan G, Mazzotta G, Gentile G, Reboldi G. ß-Blockers reduce mortality in patients undergoing high-risk non-cardiac surgery. Am J Cardiovasc Drugs 2010;10:247-59.
  5. Magee PG, Gardner TJ, Flaherty JT, Bulkley BH, Goldman RA, Gott VL. Improved myocardial protection with propranolol during induced ischemia. Circulation 1980;62:I49-56. Quon CY, Stampfli HF. Biochemical properties of blood esmolol esterase. Drug Metab Dispos 1985;13:420-4.
  6. Sum CY, Yacobi A, Kartzinel R, Stampfli H, Davis CS, Lai CM. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin Pharmacol Ther 1983;34:427-34.
  7. Cork RC, Kramer TH, Dreischmeier B, Behr S, DiNardo JA. The effect of esmolol given during cardiopulmonary bypass. Anesth Analg 1995;80:28-40.
  8. Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med 2010;11:234-8.
  9. Imura H, Caputo M, Parry A, Pawade A, Angelini GD, Suleiman MS. Age-dependent and hypoxia-related differences in myocardial protection during pediatric open heart surgery. Circulation 2001;103:1551-6.
  10. Fellahi JL, Hedoire F, Le Manach Y, Monier E, Guillou L, Riou B. Determination of the threshold of cardiac troponin I associated with an adverse postoperative outcome after cardiac surgery: a comparative study between coronary artery bypass graft, valve surgery, and combined cardiac surgery. Crit Care 2007;11:106. Immer FF, Stocker F, Seiler AM, Pfammatter JP, Bachmann D, Printzen G, et al. Troponin-I for prediction of early postoperative course after pediatric cardiac surgery. J Am Coll Cardiol 1999;33:1719-23.
  11. Taggart DP, Hadjinikolas L, Hooper J, Albert J, Kemp M, Hue D, et al. Effects of age and ischemic times on biochemical evidence of myocardial injury after pediatric cardiac operations. J Thorac Cardiovasc Surg 1997;113:728-35.